-
1 Comment
Zhejiang Orient Gene Biotech Co., Ltd is currently in a long term uptrend where the price is trading 31.7% above its 200 day moving average.
From a valuation standpoint, the stock is 23.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.9.
Based on the above factors, Zhejiang Orient Gene Biotech Co., Ltd gets an overall score of 1/5.
| Industry | Medical Devices |
|---|---|
| Sector | Healthcare |
| CurrencyCode | CNY |
| ISIN | CNE100003RM8 |
| Exchange | SHG |
| Beta | 1.96 |
|---|---|
| Dividend Yield | 9.3% |
| Market Cap | 11B |
| PE Ratio | 4.47 |
| Target Price | 377.14 |
Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells colloidal gold tests, urinalysis strips, raw materials, instruments, and molecular diagnosis products primarily in China. Its products include genetic diagnosis products; colloidal gold rapid diagnostic tests for drugs of abuse, infectious diseases, fertility, cardiac and tumor markers, and autoimmunity; dry chemical strips; bio-liquid diagnostic kits; clinical test instruments; POCT time-resolved fluor immunoassay test kits; raw materials; etc. The company also exports its products to North and South America, Europe, South Asia, Southeast Asia, the Middle East, Africa, Russia, and Australia. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688298.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
